EGFR and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC recommend biomarker testing, including EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, BRAF, and ERBB2, for actionable oncogenic driver mutations [6,7].